MRG006A

DRUG2 trials

Sponsors

Lepu Biopharma Co., Ltd.

Conditions

Advanced Solid TumorsHepatocellular Carcinoma

Phase 1

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

RecruitingNCT07093970

Lepu Biopharma Co., Ltd.Advanced Solid Tumors

Start: 2024-07-24End: 2028-12-01Target: 343Updated: 2026-01-22

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

RecruitingNCT07479485

Lepu Biopharma Co., Ltd.Hepatocellular Carcinoma

Start: 2026-04-08End: 2029-04-01Target: 160Updated: 2026-07-28

Related Papers

First-in-human phase I/II study of MRG006A, a first-in-class Glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in patients (pts) with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2026-05-27